Xencor reported $11.09M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
Amgen AMGN:US $ 1.33B 99M
Arrowhead Research ARWR:US $ 32.74M 1.12M
AstraZeneca AZN:LN 3.27B 209M
Biogen BIIB:US $ 572.6M 62.3M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Cytokinetics CYTK:US $ 42.72M 9.65M
Epizyme EPZM:US $ 24.11M 3.09M
GlaxoSmithKline GSK:LN 1.96B 726M
Johnson & Johnson JNJ:US $ 6.23B 288M
Karyopharm Therapeutics KPTI:US $ 37.34M 1.43M
Macrogenics MGNX:US $ 13.67M 2.58M
Merk MRK:US $ 2.42B 118M
Novartis NOVN:VX 3.59B 91M
Pfizer PFE:US $ 3.2B 506M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M
Seattle Genetics SGEN:US $ 220.26M 46.03M
Xencor XNCR:US $ 11.09M 182K